NEW, on 10-15-11. Marketing for back pain NSAIDS. BS!

To take a line from the Showtime show BullSh!T, by Penn & Teller, I will explain how marketing lets you believe that the common NSAID and others, ibuprofen and et al, have been marketed to letting you believe that they are "specifically targeted" to back pain or migraine headaches or whatever they can trick you into believing the drug will treat.

BULLSH!T!

stay tuned.

Just back from timeout in HI

Took the staff to HI, will be back to the mainland 9-10.

Mahalo, and I think there is a lot of data to explain thanks to Gina's hard work. Will expand on that when back to dreary SoCal.

Labor Day Holiday

My holiday is actually the start of college football season tomorrow! FINALLY.

Beside that;

I will try to update BMY's side effects of Sprycel and for cigarette smokers the biology of Chantix.

ANA 598

Hep C.
Seems this company is just stringing along investors. All things considered, they will be delisted from NASDAQ soon. It really is a shame, excusing management for questionable decisions over the last 4 years. This could have been a nice co-treatment with SOC IFN.

Rev: CELG

Secondary Cancers.

More to come.

New Postings!

I'm back and will post starting tomorrow.

I think an update to the hepatitis b drug in phase IIb from ANDS should wake up some old ghosts and get the blood pumping again.

8-23-2011---ANA598.


upcoming: an update on CELG pipeline of the blood cancer drug Revlimid.

stay tuned for some information!